drugset / Trial / NCT01009359

Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers

NCT01009359 ↗

Phase 1 Completed 22 enrolled Bayer
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.

Timeline

Start
2009-10
Primary completion
2010-07
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DPA-714 Diagnostic / imaging agent 150 mbq Intravenous
Subject DPA-714 Diagnostic / imaging agent 250 mbq Intravenous

Indications

No indication recorded.